FDA approves near-copy of Remicade for immune disorders

Federal regulators have approved an alternative version of Remicade, an expensive injected drug widely used for rheumatoid arthritis and other immune system disorders.

Without insurance, Remicade generally costs more than $30,000 annually for adults; dosage varies with the patient's weight.